Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
SV Health Investors has added $250 million to its hunt for new therapeutics for dementia, Alzheimer’s and other neurodegenerative diseases. The London-based life sciences investor
Visen Pharmaceuticals, a biotech developing much of Ascendis Pharma’s endocrine-related disease pipeline for the China market, will go public on the Hong Kong Stock Exchange
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Ampersand Biomedicines, a biotech working on medicines “similar in principle” to antibody-drug conjugates, has secured $65 million in a Series B round. Eli Lilly took
In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead drug is
European life sciences investor Sofinnova Partners disclosed a €165 million acceleration fund on Tuesday to back early-stage science in Italy, France, the United Kingdom and
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS